Pacira BioSciences (PCRX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
45.6mn → 45.0mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
+44.2% YoY in FY25 · 2.1% of revenue.
$150.5M returned vs $136.7M of FCF in FY25. The gap comes off the balance sheet (see net cash).
1¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 74.1% → 79.4%. Net margin 1.0% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 743,301.0 | 726,411.0 | 700,966.0 | 674,978.0 | 1,333,646.0 | 541,533.0 | ▲3.6% | +7.6% |
Cost of revenue | 158,109.0 | 149,749.0 | 170,428.0 | 184,669.0 | 199,295.0 | 140,255.0 | ▼12.1% | +1.7% |
Gross profit | 585,192.0 | 576,662.0 | 530,538.0 | 490,309.0 | 1,134,351.0 | 401,278.0 | ▲8.7% | +9.5% |
Research & development | 122,801.0 | 117,312.0 | 81,577.0 | 76,257.0 | 84,797.0 | 55,545.0 | ▲43.8% | +20.6% |
Selling, general & admin | 371,201.0 | 368,759.0 | 294,099.0 | 269,441.0 | 254,516.0 | 199,345.0 | ▲25.4% | +16.6% |
Total operating expenses | 549,411.0 | 557,471.0 | 603,909.0 | 402,634.0 | 1,060,688.0 | 311,354.0 | ▼7.7% | +15.7% |
Operating incomefeeds ROC rank | 35,781.0 | 19,191.0 | −73,371.0 | 87,675.0 | 60,024.0 | 89,924.0 | — | −32.0% |
Other income, net | 1,157.0 | −2,317.0 | 10,265.0 | −25,974.0 | −33,420.0 | −33,520.0 | — | — |
Pretax income | 36,938.0 | 16,874.0 | −63,106.0 | 61,701.0 | 26,604.0 | 56,404.0 | — | −26.0% |
Income tax | −789.0 | 9,840.0 | 36,454.0 | 19,746.0 | −5,214.0 | 14,424.0 | ▼73.0% | −9.1% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 37,727.0 | 7,034.0 | −99,560.0 | 41,955.0 | 31,818.0 | 41,980.0 | — | −36.0% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.94 | 0.16 | −2.15 | 0.89 | 0.34 | 0.92 | — | −35.4% |
Diluted shares (mn) | 40.83 | 45.04 | 46.24 | 51.98 | 46.54 | 45.63 | ▼2.6% | −0.3% |
| Margins | ||||||||
Gross margin73rd pct in Healthcare | 78.7% | 79.4% | 75.7% | 72.6% | 85.1% | 74.1% | ▲3.7pp | +5.3pp |
Operating margin | 4.8% | 2.6% | −10.5% | 13.0% | 4.5% | 16.6% | ▲13.1pp | −14.0pp |
Net margin55th pct in Healthcare | 5.1% | 1.0% | −14.2% | 6.2% | 2.4% | 7.8% | ▲15.2pp | −6.8pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Pacira BioSciences' revenue last fiscal year?
Pacira BioSciences reported revenue of $726.4M in fiscal 2025, up 3.6% from fiscal 2024.
What was Pacira BioSciences' net income?
Pacira BioSciences reported net income of $7.0M in fiscal 2025, a net margin of 1.0%.

